Novo Nordisk allies with Bluebird Bio to develop gene therapies

Novo Nordisk has started to collaborate with the American superstar biotech company Bluebird Bio to develop gene therapies for hemophilia and other genetic diseases.

Novo Nordisk Photo: Novo Nordisk/ PR

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try MedWatch for 14 days.

Get a trial subscription here.

Do you want a trial subscription with multiple users for yourself and your colleagues?

Read more about your options and find the contact information to our sales team here.

Related articles